S-1: Propanc Biopharma Files S-1 for Resale of 15M Shares

Propanc Biopharma, Inc. has filed an S-1 registration statement to allow for the resale of up to 15,000,000 shares of its common stock by Hexstone Capital LLC.

Summary

• Propanc Biopharma, Inc. has filed a Form S-1 registration statement with the SEC to permit the resale of up to 15,000,000 shares of its common stock by Hexstone Capital LLC.
• These shares are issuable upon conversion of Series C Preferred Stock and exercise of a warrant held by Hexstone Capital LLC.
• The company received $1,000,000 in gross proceeds from the initial sale of Series C Preferred Stock, with potential additional proceeds of $99,000,000 if the warrant is exercised.
• The company's lead product candidate, PRP, is in preclinical development for pancreatic, ovarian, and colorectal cancers.
• Propanc Biopharma has experienced significant net losses and has substantial capital requirements, raising substantial doubt about its ability to continue as a going concern.
• The company's common stock is traded on the Nasdaq Capital Market under the symbol PPCB, with a last reported sale price of $0.117 per share as of April 2, 2026.
• The company has identified material weaknesses in its internal control over financial reporting, including a lack of written documentation for internal control policies and procedures, insufficient segregation of duties, and inadequate monitoring and review controls.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's significant financial losses, ongoing cash burn, material weaknesses in internal controls, and the risk of Nasdaq delisting, despite the potential for future capital raises.

Positives

• Hexstone Capital LLC purchased 100 shares of Series C Preferred Stock for $1,000,000 in gross proceeds.
• The company has filed provisional patents for new methods to treat resistant cancer and fibrosis.
• Key findings regarding the impact of proenzymes on pancreatic ductal adenocarcinoma fibroblasts were published in Scientific Reports.
• The company filed a new provisional patent application for methods of producing a synthetic recombinant version of PRP.
• The company received Orphan Drug Designation status from the FDA for PRP for the treatment of pancreatic cancer in June 2017.

Negatives

• The company has no revenue-generating operations and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• Net loss for the six months ended December 31, 2025, was $7,929,132.
• As of December 31, 2025, the company had $561,237 in cash and an accumulated deficit of $134,482,898.
• The company's common stock is subject to penny stock rules, which may limit liquidity and make it difficult for stockholders to sell their shares.
• Trading in the company's common stock on Nasdaq has been subject to wide fluctuations.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's common stock is at risk of delisting from Nasdaq due to not meeting the minimum bid price requirement of $1.00 per share.

Risks

• The company's lead product candidate, PRP, is in early stages of development and may never become commercially viable, leading to a potential loss of investment.
• PRP may cause undesirable side effects that could negatively impact clinical trial results or limit its use.
• Successful development of products is uncertain, which could materially harm the company's results of operations.
• Clinical trials of PRP may be delayed or unsuccessful due to various factors.
• Failure to obtain regulatory approval in jurisdictions outside the U.S. will prevent marketing of PRP in those jurisdictions.
• The company faces substantial competition from major pharmaceutical and biotechnology companies.
• The company may be unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market PRP.
• The company has a limited public market for its common stock, and there is no assurance of future liquidity or market prices.
• The company's management and controlling stockholder will continue to control the company, limiting the ability of other stockholders to elect directors or influence policies.
• Future sales and issuances of common stock or rights to purchase common stock could result in substantial dilution.
• The company has identified material weaknesses in internal control over financial reporting that could lead to misstatements in financial statements.
• The company is subject to penny stock regulations, which may limit liquidity and make it difficult for stockholders to sell their shares.
• The company's common stock is quoted only on Nasdaq Capital Market, which may have an unfavorable impact on its stock price and liquidity.
• The company has no revenue-generating operations and has experienced negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern.
• The company may be unable to remain in compliance with financial or other covenants contained in its debt instruments.
• The company has incurred significant losses since inception and expects to continue to incur significant losses for the foreseeable future.
• The company may not be able to protect the confidentiality of its trade secrets.
• The company may not be able to obtain, or may experience delays in obtaining, required regulatory approvals for PRP.
• The company is dependent on third-party collaborations for the development and commercialization of PRP and other product candidates, and these collaborations may be unsuccessful.

Future Outlook

The company is in the development stage and has no revenue-generating operations. Its future success is dependent on obtaining adequate financing to fund its development activities, patent acceptance, and achieving sufficient sales to support its cost structure. The company expects to continue incurring significant expenses and operating losses for the foreseeable future.

Management Comments

• "Because PRP remains in the early stages of development and may never become commercially viable, you may lose some or all of your investment."
• "PRP may cause undesirable side effects that could negatively impact its clinical trial results or limit its use, hindering further development, subject us to possible product liability claims, and make it more difficult to commercialize PRP."
• "Because successful development of our products is uncertain, our results of operations may be materially harmed."
• "A variety of factors, either alone or in concert with each other, could result in our clinical trials of PRP being delayed or unsuccessful."
• "If we fail to obtain regulatory approval in jurisdictions outside the U.S., we will not be able to market PRP in those jurisdictions."
• "If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market PRP, we may not be successful in commercializing our product candidates if and when they are approved."
• "We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do."
• "Even if we are able to commercialize PRP, we will need to seek approval for reimbursement before it can be marketed, and it may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business."

Industry Context

StockSavvy.ai notes that Propanc Biopharma operates in the highly competitive biotechnology sector, focusing on oncology drug development. The company's reliance on preclinical data and the significant capital required for clinical trials and regulatory approvals are common challenges in this industry. The company's strategy of developing a novel proenzyme formulation for cancer treatment places it in a segment with high potential but also high risk.

Corporate Governance

Legal Proceedings

• Helena Partners, Inc. filed a complaint alleging breach of an engagement agreement and seeking a $15,000 deal deposit fee and a $250,000 break fee. Propanc Biopharma intends to vigorously defend the action.

Related Party Transactions

• The company leases its principal executive offices from North Horizon Pty Ltd., an entity owned by CEO James Nathanielsz and his wife.
• Loans have been received from institutional investors affiliated with director Josef Zelinger.
• The company issued shares of common stock to a former director in exchange for outstanding loans.

Stakeholder Impact

• Shareholders may experience dilution due to future stock issuances and potential conversion of debt and warrants.
• The limited public market and potential for penny stock classification may negatively impact liquidity for shareholders.
• The company's financial condition and ongoing losses raise concerns about the viability of investments.
• The company's controlled company status may limit shareholder influence on corporate governance and management decisions.

Next Steps

• The Selling Stockholder may offer and sell shares of Common Stock from time to time.
• The company will bear all fees and expenses incident to its obligation to register the Shares.
• The company agreed to submit to its stockholders a proposal to approve the issuance of shares of Common Stock issuable upon conversion of the Series C Preferred Stock.
• The company plans to commence a First-In-Human, Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP, subject to raising additional capital.

Key Dates

Recommendation

The company's severe financial distress, lack of revenue, significant accumulated deficit, and the ongoing risk of delisting from Nasdaq, coupled with the substantial dilution from convertible instruments and warrants, present a very high risk profile. The company's ability to continue as a going concern is in doubt, making it a speculative investment with a high probability of capital loss.

Keywords

Propanc Biopharma, S-1 Filing, SEC Registration, Common Stock Resale, Hexstone Capital LLC, Series C Preferred Stock, Warrant, PRP, Cancer Treatment, Clinical Trials, Nasdaq, PPCB, Going Concern, Internal Controls, Biotechnology